PepGen's DM1 Drug Cleared for 12.5 mg/kg Dose; Cash Runway Extended to Q4 2027
PEPG has more than doubled off its 52-week low of $1.01 on elevated volume (3.5× avg).
Summary
The DSMB cleared PGN-EDODM1 to escalate to 12.5 mg/kg in the MAD study, and an OLE 10 mg/kg cohort is mostly enrolled with no serious adverse events. This follows the August 6 safety board clearance and Q2 filing showing $117.2M in cash. The company now says its runway extends into Q4 2027, a quarter beyond the prior 'late 2027' guidance, helped by a narrower net loss after winding down the DMD program. Pivotal DM1 data is still expected in November, with 12.5 mg/kg results in H1 2027.
At the time of this announcement, PEPG was trading at $2.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $197.4M. The 52-week trading range was $1.01 to $7.80. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.